Effects of Sitagliptin on Postprandial Lipemia in Men With Type 2 Diabetes

A Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Evaluate The Effects of Sitagliptin on Postprandial Plasma Lipoprotein Concentrations in Men With Type 2 Diabetes

Sitagliptin is a potent and selective inhibitor of dipeptidyl peptidase IV (DPP-4), and has been shown to reduce fasting and postprandial glucose levels in patients with type 2 diabetes mainly through incretin hormone-mediated improvements in islet function. Although clinical studies to date indicate that fasting lipid levels are minimally affected by DPP-4 inhibitor treatment, animal studies suggested that DPP-4 inhibition reduce intestinal triglyceride (TG) absorption and apolipoprotein production and increased chylomicron catabolism. Therefore, the present study was designed to examine the effects of sitagliptin on postprandial lipemia in patients with type 2 diabetes. A possible reduction in postprandial atherogenic triglyceride-rich lipoproteins (TRL) levels by sitagliptin would add to therapeutic utility of this DPP-4 inhibitor and suggest the potential to reduce cardiovascular risk in patients with type 2 diabetes.

Study Overview

• Status: Completed
• Conditions: Diabetes Mellitus; Postprandial Lipemia
• Intervention / Treatment: Drug: Placebo; Drug: Sitagliptin

• Study Type: Interventional
• Enrollment (Actual): 36
• Phase: Phase 3

Contacts and Locations

Study Locations

• Canada
  • Quebec
    • Quebec City, Quebec, Canada, G1V 4G2
      • Laval University Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 65 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Type 2 diabetes as defined by the American Diabetes Association;
• Non-smoker;
• Body mass index between 25.0 and 40.0 kg/m2;
• Baseline HbA1c between 6.5 and 8.5%;
• Baseline fasting plasma glucose < 15.0 mmol/L;
• Plasma triglyceride levels between 1.5 and 8.0 mmol/L (135 and 710 mg/dl) at week and -4;
• Patients having received stable doses of metformin for at least 3 months before randomization;
• Subjects must be willing to give written informed consent and able to adhere to dosing schedule, visit schedule and phone follow-up assessment;
• Patients should be otherwise generally healthy, without elevations in hepatic transaminases or abnormal renal function or coagulation;
• Patients having normal TSH at screening.

Exclusion Criteria:

• Patients with extreme dyslipidemias, such as familial hypercholesterolemia will be excluded;
• Patients with type 1 diabetes, secondary form of diabetes or acute metabolic diabetic complications will be excluded;
• Patients having received or being treated with insulin or a thiazolidinedione within the past 6 months will be excluded;
• Subjects will be excluded if they have cardiovascular disease (CVD) (coronary heart disease, cerebrovascular disease or peripheral arterial disease) or if they are taking other medications known to affect lipoprotein metabolism (e.g. steroids, beta blockers, thiazide diuretics, lipid lowering agents, significant alcohol intake etc.);
• Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study;
• Individuals with a history of mental instability, drug or alcohol abuse or individuals who have been treated or are being treated for severe psychiatric illness that, in the opinion of the investigator, may interfere with optimal participation in the study;
• History of alcohol or drug abuse within the past 2 years. Patients must not take alcohol during the study;
• Disorders of the hematologic, digestive, or central nervous systems, including cerebrovascular disease and degenerative disease, that would limit study evaluation or participation;
• Known impairment of renal function (serum creatinine levels > 1.7 mg/dL for men), dysproteinemia, nephrotic syndrome, or other renal disease (24-hour urinary protein ≥3 ± 1 g);
• Active or chronic hepatobiliary or hepatic disease. In addition, patients with AST or ALT >2 x upper limit of the laboratory reference range will be excluded;
• Subjects with coagulopathy (prothrombin time [PT] or partial thromboplastin time [PTT] at Visit 1 >1.5 times control;
• Patients who are known to have tested positive for human immunodeficiency virus (HIV);
• Patients who are currently enrolled in another clinical study;
• Patients who have used any investigational drug within 30 days of the first clinic visit;
• Congestive heart failure NYHA Class III or IV. Uncontrolled cardiac arrhythmias within 3 months of study entry;
• Uncontrolled diabetes mellitus (HbA1c>8.5%) or other endocrine or metabolic disease known to influence serum lipids or lipoproteins. Clinically euthyroid subjects on replacement doses of thyroid hormone are eligible for enrollment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Quadruple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: 1; Sitagliptin 100 mg/d for 6 weeks	Drug: Sitagliptin; Sitagliptin 100 mg/d for 6 weeks
Placebo Comparator: 2; Placebo for 6 weeks	Drug: Placebo; Placebo for 6 weeks

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Measurement of the Area Under the Curve of Plasma Triglycerides (TG) Levels During Postprandial Period (Time 0,2,4,6,8 Hours)	At the end of the two 6-week interventions

Collaborators and Investigators

• Sponsor: Laval University
• Collaborators: Merck Sharp & Dohme LLC
• Investigators: Principal Investigator: Patrick Couture, MD, PhD, Laval University

Publications and helpful links

General Publications

• Tremblay AJ, Lamarche B, Deacon CF, Weisnagel SJ, Couture P. Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes. Metabolism. 2014 Sep;63(9):1141-8. doi: 10.1016/j.metabol.2014.06.004. Epub 2014 Jun 14.

Study record dates

Study Major Dates

• Study Start: February 1, 2008
• Primary Completion (Actual): January 1, 2009
• Study Completion (Actual): April 1, 2009

Study Registration Dates

• First Submitted: April 14, 2008
• First Submitted That Met QC Criteria: April 16, 2008
• First Posted (Estimate): April 17, 2008

Study Record Updates

• Last Update Posted (Estimate): December 11, 2012
• Last Update Submitted That Met QC Criteria: November 13, 2012
• Last Verified: November 1, 2012

More Information

Terms related to this study

• Keywords: Atherosclerosis; Hyperlipidemia; Diabetes mellitus; Postprandial
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Lipid Metabolism Disorders; Dyslipidemias; Diabetes Mellitus; Hyperlipidemias; Hypoglycemic Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Protease Inhibitors; Incretins; Dipeptidyl-Peptidase IV Inhibitors; Sitagliptin Phosphate
• Other Study ID Numbers: SITA001